(Q38027577)

English

Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

author name string

Robert Strohal

1

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Sergio Chimenti

2

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Gino Antonio Vena

3

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Giampiero Girolomoni

4

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

publication date

10 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Journal of Dermatological Treatment

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

199-208

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Epidemiology of psoriasis. Review and the German perspective

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Use of etanercept in the treatment of psoriasis and psoriatic arthritis

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Economic burden of psoriatic arthritis

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Psoriasis comorbidities

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Long-term prognosis in patients with psoriasis

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Metabolic disorders in patients with psoriasis and psoriatic arthritis

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Improving clinical trial design in psoriasis: Perspectives from the global dermatology community

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Use of etanercept in the dermatology setting. A review

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Phototherapy for psoriasis: what to choose and how to use: facts and controversies

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

The future of biological therapies.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

A randomized trial of etanercept as monotherapy for psoriasis

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Intermittent etanercept therapy in pediatric patients with psoriasis

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Adverse cutaneous reactions induced by TNF-alpha antagonist therapy

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Definition of treatment goals for moderate to severe psoriasis: a European consensus

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Etanercept for the treatment of severe childhood psoriasis

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2012.713462

21 January 2018

Identifiers

10.3109/09546634.2012.713462

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38027577&oldid=1737954057"